Sarah G. Injac

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “ZFTA–RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma”.

ZFTA–RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma

Cancer Discovery(2021)10.1158/2159-8290.cd-20-1066

N/A

0.681DataRank · unranked

93 citations

Yanhua Zhao, Srinidhi Varadharajan, Hsiao‐Chi Chen, Selin Jessa, Bryan Rivas +36 more

Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies

Laboratory Investigation(2021)10.1038/s41374-021-00700-8

N/A

0.494DataRank · unranked

26 citations

Holly B. Lindsay, Mari Kogiso, Yuchen Du, Frank Braun, Huiyuan Zhang +12 more

Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma

Translational Oncology(2022)10.1016/j.tranon.2022.101368

N/A

0.483DataRank · unranked

24 citations

Lin Qi, Yuchen Du, Frank Braun, Huiyuan Zhang, Lei Huang +19 more

Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10019

N/A

0.208DataRank · unranked

3 citations

Joel M. Reid, Charles G. Minard, Emasenyie Isikwei, Xiaowei Liu, Stacey L. Berg +4 more